Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)
Johnson & Johnson (JNJ) posted Non-Current Deferred Tax Liability of $6.6 billion for Q2 2026, down 5.75% sequentially from $7.0 billion in Q1 2026, and up 73.94% YoY from $3.8 billion in Q2 2025.
Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at $6.6 billion in Q2 2026.
- Quarterly Non-Current Deferred Tax Liability rose 73.94% year-over-year to $6.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.6 billion (up 73.94% YoY) and the FY2025 annual result came in at $6.8 billion, up 177.41% from the prior year.
- Non-Current Deferred Tax Liability eased to $6.6 billion in Q2 2026 per JNJ's latest filing, from $7.0 billion in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $7.5 billion in Q1 2022 and troughed at $2.4 billion in Q1 2025.
- A 5-year average of $4.5 billion and a median of $4.0 billion in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2023 and 2026: Non-Current Deferred Tax Liability plunged 46.97% in 2023, then surged 188.76% in 2026.
- Over 5 years, Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then sank by 35.44% to $3.2 billion in 2023, then slipped by 23.33% to $2.4 billion in 2024, then jumped by 177.41% to $6.8 billion in 2025, then declined by 2.69% to $6.6 billion in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $6.6 billion, $7.0 billion, and $6.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 6.61 Bn |
| Jun 28, 2026 | 6.61 Bn |
| Mar 29, 2026 | 7.01 Bn |
| Mar 29, 2026 | 7.01 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Mar 31, 2024 | 3.17 Bn |